Live feed08:30:00·123dPRReleasevia QuantisnowUltragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)ByQuantisnow·Wall Street's wire, on your screen.RARE· Ultragenyx Pharmaceutical Inc.Health Care
